Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$1.25 - $2.75 $195,370 - $429,814
156,296 Added 95.33%
320,246 $522,000
Q3 2023

Nov 13, 2023

BUY
$2.66 - $4.33 $19,532 - $31,795
7,343 Added 4.69%
163,950 $488,000
Q2 2023

Aug 11, 2023

BUY
$2.05 - $6.1 $189,854 - $564,933
92,612 Added 144.72%
156,607 $698,000
Q1 2023

May 12, 2023

BUY
$1.66 - $3.1 $15,746 - $29,406
9,486 Added 17.4%
63,995 $124,000
Q4 2022

Feb 13, 2023

SELL
$2.11 - $3.25 $454,422 - $699,939
-215,366 Reduced 79.8%
54,509 $168,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $3.14 $211,050 - $502,045
159,887 Added 145.37%
269,875 $712,000
Q2 2022

Aug 15, 2022

SELL
$0.78 - $1.9 $90,965 - $221,581
-116,622 Reduced 51.46%
109,988 $159,000
Q1 2022

May 16, 2022

BUY
$1.83 - $4.48 $123,001 - $301,118
67,214 Added 42.17%
226,610 $415,000
Q4 2021

Feb 14, 2022

BUY
$2.35 - $5.58 $374,580 - $889,429
159,396 New
159,396 $759,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.